169 related articles for article (PubMed ID: 6752024)
1. Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.
Osada Y; Mitsuyama M; Matsumoto K; Une T; Otani T; Ogawa H; Nomoto K
Infect Immun; 1982 Sep; 37(3):1285-8. PubMed ID: 6752024
[TBL] [Abstract][Full Text] [Related]
2. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections.
Osada Y; Mitsuyama M; Une T; Matsumoto K; Otani T; Satoh M; Ogawa H; Nomoto K
Infect Immun; 1982 Jul; 37(1):292-300. PubMed ID: 6809630
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.
Matsumoto K; Otani T; Une T; Osada Y; Ogawa H; Azuma I
Infect Immun; 1983 Mar; 39(3):1029-40. PubMed ID: 6341226
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of non-specific resistance to infection by muroctasin.
Otani T; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
[TBL] [Abstract][Full Text] [Related]
5. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice.
Fraser-Smith EB; Waters RV; Matthews TR
Infect Immun; 1982 Jan; 35(1):105-10. PubMed ID: 7054119
[TBL] [Abstract][Full Text] [Related]
6. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
[TBL] [Abstract][Full Text] [Related]
7. [Muramyl dipeptide and its synthetic analog as possible inducers of interleukin-2 production].
Malaĭtsev VV; Bogdanov IM; Sukhikh GT; Andronova TM
Biull Eksp Biol Med; 1985 Aug; 100(8):221-3. PubMed ID: 3875372
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
Akasaki M; Takashi T; Kita Y; Tsukada W
Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of anomeric pairs of lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine.
Kalyuzhin OV; Zemlyakov AE; Kalina NG; Mulik EL; Kuzovlev FN; Makarova OV
Bull Exp Biol Med; 2008 May; 145(5):623-5. PubMed ID: 19145298
[TBL] [Abstract][Full Text] [Related]
10. Activation of immune responses by muroctasin.
Akasaki M
Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
[TBL] [Abstract][Full Text] [Related]
11. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice.
Matsumoto K; Ogawa H; Kusama T; Nagase O; Sawaki N; Inage M; Kusumoto S; Shiba T; Azuma I
Infect Immun; 1981 May; 32(2):748-58. PubMed ID: 7019079
[TBL] [Abstract][Full Text] [Related]
13. [The immunostimulating activity of muramyl dipeptide and its derivatives].
Karsonova MI; Andronova TM; Pinegin BV; Khaitov RM
Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):104-10. PubMed ID: 10852007
[No Abstract] [Full Text] [Related]
14. The nucleotide-binding oligomerization domain-containing-2 ligand muramyl dipeptide enhances phagocytosis and intracellular killing of Escherichia coli K1 by Toll-like receptor agonists in microglial cells.
Ribes S; Adam N; Schütze S; Regen T; Redlich S; Janova H; Borisch A; Hanisch UK; Nau R
J Neuroimmunol; 2012 Nov; 252(1-2):16-23. PubMed ID: 22889567
[TBL] [Abstract][Full Text] [Related]
15. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.
Fraser-Smith EB; Matthews TR
Infect Immun; 1981 Dec; 34(3):676-83. PubMed ID: 7333666
[TBL] [Abstract][Full Text] [Related]
17. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
18. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
[TBL] [Abstract][Full Text] [Related]
19. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
[No Abstract] [Full Text] [Related]
20. Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives.
Nishimura K; Okumura H; Saiki I; Okuyama H; Azuma I
Infect Immun; 1985 Mar; 47(3):665-9. PubMed ID: 3882562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
